Before you view this Expert Consult video, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit. 

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.

Question Title

* 1. What are your credentials?

Question Title

* 2. What is your community of practice?

Question Title

* 3. Compared to the phase 3 CARTITUDE-4 clinical trial, a key difference in demographics of patients enrolled in the phase 3 KarMMa-3 clinical trial is that more than half of patients had which of the following characteristics? 

Question Title

* 4. The results of the phase 3 CARTITUDE-4 clinical trial demonstrated which of the following outcomes? 

Question Title

* 5. Which of the following has been observed in approximately 50% to 70% of patients receiving investigational bi-/trispecific antibodies for relapsed/refractory multiple myeloma? 

Question Title

* 6. All of the following are barriers to use of soluble BCMA as a biomarker in clinical practice EXCEPT?

Question Title

* 7. Which of the following types of biomarkers is correctly matched to biomarker routinely used in the management of patients with multiple myeloma? 

Question Title

* 8. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity) 

Completing the fields below does not immediately qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.

*Please note that we will not forward or sell your contact information.

( Privacy & Cookie Notice

T